Skip to main content

Differential effect of amisulpride on cognition in schizotypy: validation of models for the early identification of cognitive enhancing agents

Journal Article


Abstract


  • The cognitive impairment associated with schizophrenia is a major target for drug development but none of the drugs designed to address this problem has shown consistent efficacy. The most common causes for failure in the registration trials could be preempted by testing novel agents in milder forms of the disorder, such as schizotypy and assessing the effect with validated biomarkers. In this study we aimed to test this approach by comparing the effects of risperidone, amisulpride, and nicotine in a double-blind placebo-controlled three-centre study on the cognitive performance in schizotypy.

Authors


  •   Koychev, Ivan (external author)
  •   McMullen, Katrina (external author)
  •   Lees, Jane (external author)
  •   Dadhiwala, Rukiya (external author)
  •   Grayson, Lois (external author)
  •   Perry, Charlotte (external author)
  •   Schmechtig, Anne (external author)
  •   Walters, James (external author)
  •   Craig, Kevin J. (external author)
  •   Dawson, Gerard R. (external author)
  •   Dourish, Colin T. (external author)
  •   Ettinger, Ulrich (external author)
  •   Wilkinson, Lawrence (external author)
  •   Williams, Steven (external author)
  •   Deakin, John Francis William. (external author)
  •   Barkus, Emma

Publication Date


  • 2013

Citation


  • Koychev, I., McMullen, K., Lees, J., Dadhiwala, R., Grayson, L., Perry, C., Schmechtig, A., Walters, J., Craig, K. J., Dawson, G. R., Dourish, C. T., Ettinger, U., Wilkinson, L., Williams, S., Deakin, J. William. & Barkus, E. (2013). Differential effect of amisulpride on cognition in schizotypy: validation of models for the early identification of cognitive enhancing agents. Lancet, 381 S59-S59.

Ro Metadata Url


  • http://ro.uow.edu.au/sspapers/595

Start Page


  • S59

End Page


  • S59

Volume


  • 381

Abstract


  • The cognitive impairment associated with schizophrenia is a major target for drug development but none of the drugs designed to address this problem has shown consistent efficacy. The most common causes for failure in the registration trials could be preempted by testing novel agents in milder forms of the disorder, such as schizotypy and assessing the effect with validated biomarkers. In this study we aimed to test this approach by comparing the effects of risperidone, amisulpride, and nicotine in a double-blind placebo-controlled three-centre study on the cognitive performance in schizotypy.

Authors


  •   Koychev, Ivan (external author)
  •   McMullen, Katrina (external author)
  •   Lees, Jane (external author)
  •   Dadhiwala, Rukiya (external author)
  •   Grayson, Lois (external author)
  •   Perry, Charlotte (external author)
  •   Schmechtig, Anne (external author)
  •   Walters, James (external author)
  •   Craig, Kevin J. (external author)
  •   Dawson, Gerard R. (external author)
  •   Dourish, Colin T. (external author)
  •   Ettinger, Ulrich (external author)
  •   Wilkinson, Lawrence (external author)
  •   Williams, Steven (external author)
  •   Deakin, John Francis William. (external author)
  •   Barkus, Emma

Publication Date


  • 2013

Citation


  • Koychev, I., McMullen, K., Lees, J., Dadhiwala, R., Grayson, L., Perry, C., Schmechtig, A., Walters, J., Craig, K. J., Dawson, G. R., Dourish, C. T., Ettinger, U., Wilkinson, L., Williams, S., Deakin, J. William. & Barkus, E. (2013). Differential effect of amisulpride on cognition in schizotypy: validation of models for the early identification of cognitive enhancing agents. Lancet, 381 S59-S59.

Ro Metadata Url


  • http://ro.uow.edu.au/sspapers/595

Start Page


  • S59

End Page


  • S59

Volume


  • 381